Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia
Status:
Unknown status
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate if the treatment with Alemtuzumab (after I or II line
chemotherapy) administered for 6 weeks followed by 4 months maintenance treatment compared to
a control group can reduce disease activity/residual disease and thereby delay the
reoccurrence of the CLL disease.